J. Riess

发表

A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.

A. Butte, J. Dudley, P. Khatri, 2013, Cancer discovery.

siRNA-directed inhibition of HIV-1 infection

J. Lieberman, D. Dykxhoorn, P. Sharp, 2002, Nature Medicine.

Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

Paul Baas, Ignacio I. Wistuba, Robert Pirker, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

B. Costello, J. Riess, B. Goh, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer

H. Wakelee, J. Riess, A. Logan, 2012, Cancer investigation.

Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors

Edward J. Kim, J. Riess, K. Kelly, 2021, Cancer Chemotherapy and Pharmacology.

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

A. Tafreshi, J. Riess, M. Pietanza, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.

J. Riess, J. Brahmer, A. Calles, 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

J. Riess, D. Gandara, J. Keck, 2018, Molecular Cancer Therapeutics.

Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)

J. Riess, D. Gandara, P. Mack, 2021, Clinical lung cancer.

Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Non – Small Cell Lung Cancer, Version 3.2022

Joe Y. Chang, D. Ettinger, L. Chirieac, 2022 .

A Population-Based Study of Incidence and Survival of 1588 Thymic Malignancies: Results From the California Cancer Registry.

J. Riess, R. Cress, P. Lara, 2019, Clinical lung cancer.

Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design.

S. Cherry, L. Nardo, J. Riess, 2020, Clinical lung cancer.

Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer

A. Madabhushi, M. Mino‐Kenudson, R. Herbst, 2022, Journal for ImmunoTherapy of Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer

J. Riess, D. Gandara, P. Lara, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer.

J. Neal, J. Riess, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer.

J. Neal, J. Riess, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era.

J. Riess, D. Gandara, Z. Lwin, 2013, Journal of thoracic disease.

Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.

J. Riess, D. Camidge, A. Mitra, 2021, Clinical lung cancer.

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.

J. Riess, E. Felip, L. Paz-Ares, 2019, Clinical lung cancer.

Pruritus as a Paraneoplastic Symptom of Thymoma.

J. Shrager, J. Neal, H. Wakelee, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.

J. Riess, M. Hellmann, H. Rizvi, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OA06.01 Clinical Utility of Circulating Tumor DNA (ctDNA) Analysis by Digital next Generation Sequencing of over 5,000 Advanced NSCLC Patients

S. Mortimer, J. Riess, D. Gandara, 2017 .

Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

J. Riess, J. Heymach, M. Hellmann, 2019, Journal of Clinical Oncology.

A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients (NCI 10327): Rationale and Study Design

Ian R. Lanza, S. Cherry, L. Nardo, 2021 .

Abstract CT169: Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5)

C. Dooms, M. Socinski, J. Riess, 2021, Clinical Trials.

Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma.

D. Richman, J. Riess, C. Phan, 2019, Clinical lung cancer.

A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer

Edward J. Kim, J. Riess, K. Kelly, 2022, Cancer Chemotherapy and Pharmacology.

A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Omar H. Butt, Alokkumar Jha, M. Bonnen, 2020, Cancer Cell.

SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping

J. Riess, T. Shaffer, P. Martínez, 2021, JTO clinical and research reports.

Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA).

R. West, L. Tian, Y. Natkunam, 2014 .

EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade.

J. Riess, D. Gandara, F. Knollmann, 2019, Clinical lung cancer.

Prevalence of ARID1A Mutations in Cell-Free Circulating Tumor DNA in a Cohort of 71,301 Patients and Association with Driver Co-Alterations

J. Riess, D. Gandara, H. Lenz, 2022, Cancers.

Treatment of Leptomeningeal Spread of NSCLC: A Continuing Challenge

H. Wakelee, J. Riess, S. Nagpal, 2012, Current Treatment Options in Oncology.

Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC

C. Paweletz, P. Jänne, J. Riess, 2021, JCO precision oncology.

Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors

Chuong D. Hoang, L. Tian, A. Leung, 2017, Journal of thoracic imaging.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Ross Camidge, Vamsidhar Velcheti, Thomas Filleron, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Alokkumar Jha, M. Bonnen, S. Shete, 2020, The Lancet.

A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non–Small Cell Lung Cancer

Stephen C. Grubb, Michael W. Lloyd, C. Bult, 2022, bioRxiv.

Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer

L. Beckett, J. Riess, D. Gandara, 2013, Investigational New Drugs.

A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer

Sourav Bandyopadhyay, J. Roth, J. Riess, 2021, bioRxiv.

ROS1

J. Riess, Leslie G. Oesterich, 2019, Targeted Therapies for Lung Cancer.

Diverse EGFR Exon 20 Insertions and Co‐Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

J. McPherson, P. Stephens, J. Riess, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors

J. Gregg, E. Sokol, J. Riess, 2021, Translational oncology.

Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations

J. Riess, J. Chen, 2020, Current Treatment Options in Oncology.

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Yvonne A. Evrard, Michael W. Lloyd, Jeffrey H. Chuang, 2021, Nature Genetics.

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer

L. Beckett, J. Riess, K. Kelly, 2021, JCO precision oncology.

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases

S. Mortimer, J. Riess, D. Gandara, 2020, Cancer.

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

Maximilian Diehn, Charles Swanton, Wei Wu, 2017, Nature Genetics.

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer

S. Asthana, E. Collisson, J. Riess, 2015, Nature Medicine.

GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray.

R. West, C. Hoang, J. Neal, 2015, Anticancer research.

Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors

R. West, L. Tian, H. Kohrt, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database

J. Shrager, H. Wakelee, J. Riess, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer

N. Hacohen, S. Digumarthy, C. Stewart, 2022, bioRxiv.

Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors

J. Riess, J. Chen, 2020, Journal of thoracic disease.

Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.

R. West, J. Neal, H. Wakelee, 2015, Lung cancer.

Increased Galectin-1 Expression in Thymic Epithelial Tumors.

R. West, J. Neal, H. Wakelee, 2019, Clinical lung cancer.

Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.

C. Bult, E. Liu, J. Riess, 2015, Clinical lung cancer.

Phase I study of INC280 plus erlotinib in patients with MET expressing adenocarcinoma of the lung.

L. Beckett, J. Riess, K. Kelly, 2015 .

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib

Jing Wang, J. Roth, J. Riess, 2021, bioRxiv.

Application of Machine Learning to Metabolomic Profile Characterization in Glioblastoma Patients Undergoing Concurrent Chemoradiation

O. Fiehn, J. Riess, R. Hodeify, 2023, Metabolites.

A Common Cell of Origin for Inflammatory Myofibroblastic Tumor and Lung Adenocarcinoma with ALK rearrangement.

A. Borowsky, J. Riess, B. Alexander, 2022, Clinical lung cancer.

Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors

J. Riess, M. Rosenzweig, V. Miller, 2020, Lung Cancer.

MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation.

J. Gregg, J. Riess, V. Miller, 2019, The oncologist.

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC

G. Giaccone, J. Gregg, P. Stephens, 2018, PloS one.

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer

J. Neal, H. Wakelee, J. Riess, 2013, British Journal of Cancer.

Casting a wide net: HSP90 inhibition to circumvent resistance to TKIs in EGFR-mutated and ALK-rearranged NSCLC

J. Riess, P. Lara, 2015 .

ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.

H. Wakelee, J. Nieva, J. Riess, 2012, Lung cancer.

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.

J. Riess, R. Doebele, R. Nichols, 2018, Cancer research.

A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements.

J. Neal, H. Wakelee, J. Riess, 2013, Clinical lung cancer.

Evolution and clinical impact of genetic epistasis within EGFR-mutant lung cancers

V. Wang, C. Swanton, J. Chabon, 2017, bioRxiv.

Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.

H. Wakelee, J. Riess, 2012, Clinical advances in hematology & oncology : H&O.

New and emerging developments in extensive-stage small cell lung cancer therapeutics

J. Riess, P. Lara, M. Parikh, 2016, Current opinion in oncology.

Left behind? Drug discovery in extensive-stage small-cell lung cancer.

J. Riess, P. Lara, 2014, Clinical lung cancer.

Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy.

Summer S. Han, J. Neal, H. Wakelee, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.

K. Ramchandran, J. Neal, H. Wakelee, 2019, Lung cancer.

Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.

K. Ramchandran, J. Neal, H. Wakelee, 2014, Clinical lung cancer.

A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib.

J. Neal, H. Wakelee, J. Riess, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study

S. Digumarthy, J. Neal, H. Wakelee, 2023, JTO clinical and research reports.

Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications.

J. Riess, K. Kelly, D. Gandara, 2014, Clinical Lung Cancer.

Abstract 4610: A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors

A. Butte, J. Dudley, P. Khatri, 2014 .

Multidisciplinary Care.

J. Riess, M. Daly, 2016, Cancer treatment and research.

1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib

J. Riess, B. Cho, I. Okamoto, 2021, Annals of Oncology.

A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trial

P. Jänne, J. Riess, S. Ou, 2020 .

LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%

A. Tafreshi, J. Riess, M. Pietanza, 2020 .

Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

J. Riess, V. Sinha, K. Mayawala, 2018, Clinical Cancer Research.

Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry.

J. Riess, K. Kelly, D. Gandara, 2017, Lung cancer.

A Case of Osimertinib-Induced Eosinophilic Pneumonia.

J. Riess, N. Stollenwerk, Z. Karanjawala, 2022, Clinical lung cancer.

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).

Philip Smith, J. Riess, B. Cho, 2021, Clinical lung cancer.

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Predictors of Survival in Small Cell Lung Cancer (SCLC) Patients (pts) < 50 Years of Age: Results from the California Cancer Registry (CCR) - eScholarship

J. Riess, K. Kelly, D. Gandara, 2015 .

Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.

J. Neal, H. Wakelee, J. Riess, 2015, Lung cancer.

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations

J. Riess, R. Doebele, T. Stinchcombe, 2019, Clinical Cancer Research.

Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer.

J. Riess, D. Gandara, U. Malapelle, 2023, Hematology/oncology clinics of North America.

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

N. Hacohen, S. Digumarthy, C. Stewart, 2023, Nature Genetics.

Functional Outcomes After De-escalated Chemoradiation Therapy for Human Papillomavirus-Positive Oropharyngeal Cancer: Secondary Analysis of a Phase 2 Trial.

J. Riess, J. Hegde, M. Daly, 2017, International journal of radiation oncology, biology, physics.

Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study.

S. Groshen, C. Paweletz, P. Jänne, 2019, Journal of Clinical Oncology.

Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC

J. Riess, C. Blakely, 2019, Expert review of anticancer therapy.

P76.27 ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib

J. Riess, Paul D. Smith, I. Okamoto, 2021 .

Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.

J. Neal, H. Wakelee, J. Riess, 2020, Journal of Clinical Oncology.

EGFR mutation status and brain metastases in non-small cell lung cancer: an understudied problem

J. Riess, S. Nagpal, 2013 .

Oral 1.01: Phase II trial of amrubicin in patients with previously treated advanced thymic malignancies

K. Ramchandran, J. Neal, H. Wakelee, 2015 .

Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM).

K. Ramchandran, J. Neal, H. Wakelee, 2015 .

Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling

J. Riess, S. Ou, J. Bendell, 2020, European Journal of Cancer.

A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS.

J. Neal, H. Wakelee, J. Sage, 2020, Cancer treatment and research communications.

Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors.

M. van de Rijn, Y. Natkunam, J. Neal, 2023, JTO clinical and research reports.

Imaging of lung cancer.

J. Riess, Lisa Brown, David Cooke, 2023, Current problems in cancer.

Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer.

J. Riess, K. Kelly, D. Gandara, 2017, Clinical lung cancer.

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck

J. Riess, A. Colevas, D. Boothroyd, 2018, The oncologist.

Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC.

S. Digumarthy, G. Scagliotti, L. Landi, 2023, Cancer discovery.

P26.02 A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results

J. Riess, R. Doebele, K. Jones, 2021, Journal of Thoracic Oncology.

Patient‐reported quality‐of‐life outcomes after de‐escalated chemoradiation for human papillomavirus‐positive oropharyngeal carcinoma: Findings from a phase 2 trial

Jordan H. Garst, J. Riess, J. Hegde, 2018, Cancer.

P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy

J. Riess, Paul D. Smith, P. Jewsbury, 2019, Journal of Thoracic Oncology.

Novel Clinical Trial Designs in Pursuit of Precision Oncology: Lung-MAP As a Model.

J. Riess, D. Gandara, C. Rolfo, 2021, Clinical lung cancer.

Erratum: siRNA-directed inhibition of HIV-1 infection (Nature Medicine (2002) 8 (681-686))

J. Lieberman, D. Dykxhoorn, P. Sharp, 2003 .

siRNA-directed inhibition of HIV-1 infection

J. Lieberman, D. Dykxhoorn, P. Sharp, 2003, Nature Medicine.

Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).

Abidemi K. Adeniji, J. Riess, E. Felip, 2022, Lung cancer.

In Search of an Oncogene Driver for Squamous Lung Cancer.

J. Riess, D. Gandara, P. Lara, 2018, JAMA oncology.

Evolution and clinical impact of genomic alterations detectable in circulating tumor DNA of 1150 advanced EGFR-mutant (mt) lung cancer patients.

V. Wang, J. Riess, R. Doebele, 2017 .

656MO Phase I study of M6620 (VX-970, berzosertib) in combination with cisplatin and XRT in patients with locally advanced head and neck squamous cell carcinoma

J. Riess, T. Owonikoko, A. Bhatia, 2022, Annals of Oncology.

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Steven B. Neuhauser, Yvonne A. Evrard, Michael W. Lloyd, 2019, Nature Genetics.

Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.

S. Groshen, C. Paweletz, H. Wakelee, 2022, Journal of Clinical Oncology.

Profile Characterization of Biogenic Amines in Glioblastoma Patients Undergoing Standard-of-Care Treatment

O. Fiehn, J. Riess, I. Tagkopoulos, 2023, Biomedicines.

Patient-derived tumor xenografts in humanized NSG-SGM3 mice: A new immuno-oncology platform.

J. Banchereau, J. Riess, K. Palucka, 2016 .

Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial.

J. Riess, K. Schalper, S. Shiao, 2023, Nature communications.

Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions.

J. Riess, D. Gandara, J. Keck, 2017 .

Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC

J. Riess, D. Gandara, C. Blakely, 2022, JTO Clinical and Research Reports.

Abstract LB001: Anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancers

P. Jänne, J. Riess, H. Burris, 2021, Experimental and Molecular Therapeutics.

Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

M. Galsky, J. Riess, M. Robson, 2023, medRxiv.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.

J. Riess, M. Hellmann, H. Rizvi, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.

M. Aladjem, J. Riess, C. Redon, 2023, JAMA oncology.

siRNA-directed inhibition of HIV-1 infection

J. Lieberman, D. Dykxhoorn, P. Sharp, 2002, Nature Medicine.

Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment

P. Jänne, P. Ascierto, J. Riess, 2023, Molecular Cancer Therapeutics.